Sharma Bhawna, Sreenivasan Priya, Biswal Manisha, Mahajan Varun, Suri Vikas, Singh Sehgal Inderpaul, Ray Pallab, Dutt Puri Goverdhan, Bhalla Ashish, Narayana Yaddanapudi Lakshmi, Koushal Vipin, Angrup Archana
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. E-mail:
Department of Anaesthesia, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Qatar Med J. 2021 Oct 25;2021(3):62. doi: 10.5339/qmj.2021.62. eCollection 2021.
Bacterial co-pathogens are common in various viral respiratory tract infections, leading to increased disease severity and mortality. Still, they are understudied during large outbreaks and pandemics. This study was conducted to highlight the overall burden of these infections in COVID-19 patients admitted to our tertiary care hospital, along with their antibiotic susceptibility patterns.
During the six-month study period, clinical samples (blood samples, respiratory samples, and sterile body fluids, including cerebrospinal fluid [CSF]) of COVID-19 patients with suspected bacterial coinfections (at presentation) or secondary infections (after 48 hours of hospitalization) were received and processed for the same.
Clinical samples of 814 COVID-19 patients were received for bacterial culture and susceptibility. Out of the total patient sample, 75% had already received empirical antibiotics before the samples were sent for analysis. Overall, 17.9% of cultures were positive for bacterial infections. Out of the total patients with bacterial infection, 74% (108/146) of patients had secondary bacterial infections (after 48 hours of hospitalization) and 26% (38/146) had bacterial coinfections (at the time of admission). Out of the 143 total isolates obtained, the majority (86%) were gram-negative organisms, of which was the commonest organism (35.6%), followed by (18.1%). The majority (50.7%) of the pathogenic organisms reported were multidrug resistant.
The overall rate of secondary bacterial infections (SBIs) in our study was lower (7.9%) than reported by other studies. A rational approach would be to adhere to the practice of initiating culture-based guidance for antibiotics and to restrict unnecessary empirical antimicrobial therapy.
细菌共病原体在各种病毒性呼吸道感染中很常见,会导致疾病严重程度和死亡率增加。然而,在大规模疫情和大流行期间,它们的研究仍不充分。本研究旨在突出入住我们三级医院的新冠肺炎患者中这些感染的总体负担及其抗生素敏感性模式。
在为期六个月的研究期间,接收了疑似细菌合并感染(就诊时)或继发感染(住院48小时后)的新冠肺炎患者的临床样本(血液样本、呼吸道样本和无菌体液,包括脑脊液[CSF])并进行处理。
共接收了814例新冠肺炎患者的临床样本进行细菌培养和药敏试验。在所有患者样本中,75%在样本送检分析前已接受经验性抗生素治疗。总体而言,17.9%的培养物细菌感染呈阳性。在所有细菌感染患者中,74%(108/146)的患者发生了继发细菌感染(住院48小时后),26%(38/146)的患者发生了细菌合并感染(入院时)。在总共获得的143株分离株中,大多数(86%)是革兰氏阴性菌,其中 是最常见的菌种(35.6%),其次是 (18.1%)。报告的致病生物中大多数(50.7%)对多种药物耐药。
我们研究中继发细菌感染(SBIs)的总体发生率(7.9%)低于其他研究报告的发生率。合理的方法是坚持基于培养结果指导使用抗生素的做法,并限制不必要的经验性抗菌治疗。